Keywords: cost-effectiveness, lilly, zyprexa, new, study, presented, wcbp

"Cost-Effectiveness" Of Lilly's Zyprexa

Article | 03 July 1997

Print This

A new study, presented at the WCBP by Dennis Reviki of MedtapInternational, Maryland, USA, demonstrates that Eli Lilly's Zyprexa (olanzapine) ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in